Loading
New medicines approved in the United States from 2001 to 2021 reached approval in Iran, when they did at all, more than five years later on average, and cancer medicines were no faster.
The authors compared new molecular entities approved by the US Food and Drug Administration, the European Medicines Agency, Japan's Pharmaceuticals and Medical Devices Agency and the Iran Food and Drug Administration between 2001 and 2021, using the Iranian government's official medicines list and the agencies' own records, and measured absolute and relative drug lag by therapeutic area of the Anatomical Therapeutic Chemical classification.
It is the only published measure OnCo found of how long new cancer medicines take to be approved in Iran, and it puts the delay in years rather than months.
Shares Regulatory divergence between regions, Most of the world has almost no cancer care.
Shares Iran Food and Drug Administration (IFDA), Most of the world has almost no cancer care.
Shares Regulatory divergence between regions, Most of the world has almost no cancer care.
Shares Regulatory divergence between regions, Most of the world has almost no cancer care.
Shares Regulatory divergence between regions, Most of the world has almost no cancer care.
Shares Regulatory divergence between regions, Most of the world has almost no cancer care.
Shares Regulatory divergence between regions, Most of the world has almost no cancer care.
Shares Regulatory divergence between regions, Most of the world has almost no cancer care.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/